

Baseline Serum Biomarkers do Not Predict Dupilumab Treatment Response in Adults With Moderate-to-Severe Atopic Dermatitis

Stephan Weidinger¹, Lisa A. Beck², Marjolein S. de Bruin-Weller³, Jacob P. Thyssen⁴, Kenji Kabashima⁵, Emma Guttman-Yassky⁶, Cezmi A. Akdis⁷, Zhen Chen⁸, Noah A. Levit⁸, Mike Bastian⁹

¹University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; ²University of Rochester Medical Center, Rochester, NY, USA; ³University Medical Center Utrecht, Utrecht, The Netherlands; ⁴Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark; ⁵Kyoto University Graduate School of Medicine, Kyoto, Japan; ⁶Icahn School of Medicine at Mount Sinai Medical Center, New York, NY, USA; ⁷Swiss Institute of Allergy and Asthma Research, University of Zurich, Zurich, Switzerland; ⁸Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; ⁹Sanofi, Frankfurt, Germany

OBJECTIVE

- This new analysis based on 16-week, phase 3 studies reports whether pre-treatment levels of common serum biomarkers can predict treatment response to dupilumab in adults with moderate-to-severe atopic dermatitis (AD)

METHODS

Study design

- LIBERTY AD SOLO 1 and 2 (NCT02277743, NCT02277769), two randomized, double-blind studies, included patients ≥ 18 years old with moderate-to-severe AD treated with dupilumab 300 mg every 2 weeks (q2w) or placebo for 16 weeks

Analysis

- Correlation between change in Eczema Area Severity Index (EASI) score and log of baseline IgE, CC chemokine ligand 17 (CCL17) (previously referred to as thymus and activation-regulated chemokine [TARC]) and lactate dehydrogenase (LDH) at baseline was assessed using Spearman correlation coefficient (ρ)

Safety

- Overall safety was consistent with the known dupilumab safety profile

CONCLUSION

- Baseline levels of total IgE, CCL17 and LDH do not predict treatment response to dupilumab, as measured by EASI, in adults with moderate-to-severe AD

RESULTS

Figure 1. Very weak correlation between change in EASI score at Week 16 and log of baseline total IgE.





Figure 2. Weak correlation between change in EASI score at Week 16, log of baseline CCL17 and log of baseline LDH.



Acknowledgments: Data first presented at the 2023 Deutschen Dermatologischen Gesellschaft (DDG) - 52nd Tagung – April 26 - 29, 2023 (Berlin, Germany). Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifiers: NCT02277743, NCT02277769. Medical writing/editorial assistance was provided by Marie Vidal, PhD of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guideline.

Disclosures: **Weidinger S:** German Atopic Dermatitis Registry TREATgermany – co-principal investigator; LEO Pharma, L'Oréal, Novartis, Pfizer – institutional research grants; Incyte, LEO Pharma, Novartis, Regeneron Pharmaceuticals Inc., Sanofi – consultancies; AbbVie, Galderma, LEO Pharma, Regeneron Pharmaceuticals Inc., Sanofi – lectured at educational events; clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic eczema. **Beck LA:** AbbVie, AstraZeneca, Benevolent^{td}, DermTech, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Principia Biopharma, RAPT Therapeutics, Regeneron Pharmaceuticals Inc., Sanofi, sanofi-aventis, Stealth BioTherapeutics – consultant; AbbVie, AstraZeneca, DermTech, Kiniksa Pharmaceuticals, LEO Pharma, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi – investigator; 3M, Gilead, Medtronic, Moderna – stock ownership. **de Bruin-Weller MB:** Regeneron Pharmaceuticals Inc., Sanofi – Principal Investigator, advisory board member, consultant; AbbVie, Pfizer – Principal Investigator, advisory board member; Eli Lilly, UCB – advisory board member. **Thyssen JP:** AbbVie, Eli Lilly, LEO Pharma, Sanofi – investigator; Eli Lilly, LEO Pharma, Sanofi – speaker/advisor. **Kabashima K:** Japan Tobacco, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Ono Pharmaceutical, Procter & Gamble, Sanofi, Taiho Pharma, Torii Pharmaceutical – consulting fees, honoraria, grant support, and/or lecturing fees. **Guttman-Yassky E:** AbbVie, Anacor Pharmaceuticals, Asana Biosciences, Celgene, Celsus Therapeutics, Dermira, Eli Lilly, Galderma, Glenmark, Janssen, Kiowa Kirin, LEO Pharma, MedImmune, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Stiefel GSK, Vitae Pharmaceuticals – consultant and grants/honoraria; Celgene, Eli Lilly, Glenmark, LEO Pharma, MedImmune, Regeneron Pharmaceuticals Inc., – investigator; Asana Biosciences, Celgene, Celsus Therapeutics, Dermira, Galderma, Glenmark, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Stiefel GSK, Vitae Pharmaceuticals – advisory board member. **Akdis CA:** Novartis Research Institutes, SciBase, Stanford University, Swiss National Science Foundation, European Union (EU CURE, EU Syn-Air-G) – research grants; BMS, GSK, Novartis, Sanofi-Regeneron Pharmaceuticals Inc., SciBase, Stanford University Sean Parker Asthma Allergy Center – advisory board member; EAACI Guidelines on Environmental Science in Allergic diseases and Asthma – Co-Chair; Allergy – Editor-in-Chief. **Chen Z, Levit NA:** Regeneron Pharmaceuticals Inc. – employees and shareholders. **Bastian M:** Sanofi – employee, may hold stock and/or stock options in the company.

Presented at the 5th Annual Revolutionizing Atopic Dermatitis (RAD) Conference; Washington, DC, USA; April 29–May 1, 2023.